AZ, Daiichi Sankyo Team Up for Development, Commercialization of Nasal Flu Vaccine in Japan

    September 3, 2015
    AstraZeneca plc (AZ) and Daiichi Sankyo announced on September 2 that Daiichi Sankyo and AZ’s global biologics research and development arm MedImmune have entered into a license agreement for AZ’s nasal spray formulation of the influenza vaccine FluMist Quadrivalent (brand...read more